Dr Andrew M. Kiselica, narrating a new blog he wrote for the Dementia Researcher website.

Why are preclinical Alzheimer’s trials struggling to show results? Andrew and colleagues argue the issue may not just be biology or timing, but how we define “normal.” By grouping cognitively unimpaired individuals together, trials overlook meaningful differences in subtle symptoms. This blog explores how recognising objective subtle cognitive decline, supported by digital tools and refined measures, could improve participant selection and increase the chances of detecting real treatment effects.

Find the original text, and narration here on our website.

https://www.dementiaresearcher.nihr.ac.uk/blog-why-normal-cognition-is-hindering-preclinical-alzheimers-trials/

--

Dr Andrew M. Kiselica is an Associate Professor at the University of Georgia whose work focuses on early detection of cognitive decline in Alzheimer’s disease. He contributes to the Working Group on Objective Subtle Cognitive Decline in Alzheimer’s Disease.

Follow us on social media:

• https://www.instagram.com/dementia_researcher/
• https://www.facebook.com/Dementia.Researcher/
• https://www.twitter.com/demrescommunity
• https://www.linkedin.com/company/dementia-researcher
• https://bsky.app/profile/dementiaresearcher.bsky.social

Download and Register with our Community App:

https://www.onelink.to/dementiaresearcher